TCRT Alaunos Therapeutics
- 1.3200
- +0.1600+13.79%
Alaunos Therapeutics News
Alaunos Therapeutics Announces Executive Financial Leadership Changes
Alaunos Therapeutics Regains Nasdaq Listing Compliance
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersCogent Biosciences (NASDAQ:COGT) shares rose 45.6% to $7.95 during Wednesday's pre-market session. The company's market cap stands at $684.6 million. Lineage Cell Therapeutics (AMEX:LCTX) stock
TCRT, NXT and MINM Among Mid-day Movers
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Alaunos Therapeutics To Carry Out 1-for-15 Reverse Stock Split On February 1st, 2024
January 30th - $Alaunos Therapeutics(TCRT.US)$ is about to implement a 1-for-15 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from February 1st, 2024.$Alaunos
Express News | Alaunos Therapeutics Appoints Dale Curtis Hogue As Interim CEO, Effective Jan. 20 2024; Hogue Will Continue Serving On The Board
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersMesoblast (NASDAQ:MESO) shares increased by 22.1% to $2.1 during Friday's pre-market session. The company's market cap stands at $180.2 million. Sangamo Therapeutics (NASDAQ:SGMO) stock rose 20
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAkso Health Group (NASDAQ:AHG) stock increased by 23.4% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $30.1 million. Assure Hldgs (NASDAQ:ION
Should You Buy Alaunos Therapeutics Inc (TCRT) Stock on Friday?
Alaunos Therapeutics Inc (TCRT) stock has risen 142.86% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
12 Health Care Stocks Moving In Friday's Intraday Session
GainersAinos (NASDAQ:AIMD) stock moved upwards by 74.0% to $3.01 during Friday's regular session. The market value of their outstanding shares is at $14.0 million. Elevation Oncology (NASDAQ:ELEV) sto
On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consultin
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiomerica (NASDAQ:BMRA) shares rose 54.5% to $1.53 during Tuesday's pre-market session. The market value of their outstanding shares is at $25.7 million. Cingulate (NASDAQ:CING) stock increased
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersBiomerica (NASDAQ:BMRA) shares rose 71.7% to $1.7 during Monday's pre-market session. The market value of their outstanding shares is at $28.5 million. Arcutis Biotherapeutics (NASDAQ:ARQT) sha
12 Health Care Stocks Moving In Friday's After-Market Session
GainersMira Pharmaceuticals (NASDAQ:MIRA) shares moved upwards by 9.2% to $3.59 during Friday's after-market session. The market value of their outstanding shares is at $53.0 million. TC BioPharm (Hol
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersPaxMedica (NASDAQ:PXMD) shares rose 33.6% to $1.07 during Wednesday's regular session. The market value of their outstanding shares is at $1.1 million. Impel Pharmaceuticals (NASDAQ:IMPL) share
Recap: Alaunos Therapeutics Q3 Earnings
Alaunos Therapeutics (NASDAQ:TCRT) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:30 AM.Here's what investors need to know about the announcement.EarningsAlaunos Therapeutics mis
Alaunos Therapeutics Q3 EPS $(0.04), Same As Last Year
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.04) per share. This is unchanged from the same period last year.
Alaunos Therapeutics Continues To Explore Potential Strategic Alternatives; Says Has Reduced Its Workforce By Approximately 80% To Date In Order To Streamline Organization And To Maximize Cash Runway
Alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.
Press Release: Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives -- TCR-T Library Phase 1/2 trial achieved an 87% dise
Analysis
Price Target
No Data
